A Randomized Double-Blind Placebo-Controlled. Multi-center Proof-of-Mechanism Phase 2a Study to Evaluate the Safety Tolerability and efficacy of TAK-018 (EB8018) for the Prevention of Post-Operative Crohn s Disease Recurrence.

Go Back to All Clinical Trials

A Randomized Double-Blind Placebo-Controlled. Multi-center Proof-of-Mechanism Phase 2a Study to Evaluate the Safety Tolerability and efficacy of TAK-018 (EB8018) for the Prevention of Post-Operative Crohn s Disease Recurrence.

Brief description of study

The main purpose of this study is to evaluate how safe and tolerable a drug called TAK-018 (or sibofimloc,the “Takeda Study Drug”) is in people with Crohn’s disease (CD) after bowel resection. The study will also look at whether TAK-018 can stop CD from recurring after surgery. TAK-018 is an investigational drug. “Investigational” means that the study drug being tested has not yet been approved by the United States Food and Drug Administration (FDA). TAK-018 is a tablet which is taken orally (by mouth).

Clinical Study Identifier: s19-00438

ClinicalTrials.gov Identifier: NCT03709628

Clinical Research Studies

A Randomized Double-Blind Placebo-Controlled. Multi-center Proof-of-Mechanism Phase 2a Study to Evaluate the Safety Tolerability and efficacy of TAK-018 (EB8018) for the Prevention of Post-Operative Crohn s Disease Recurrence.

Brief description of study

Recruitment Status

212-263-4432

646-754-7432